Evimar 13 0.5 ml (IM Injection)

Indications

• Active immunization against pneumococcal disease
• Recommended for children aged 2 years, adolescents, and adults

Pharmacology

• Prepared from purified pneumococcal capsular polysaccharide antigens
• Derived from 23 serotypes accounting for approximately 90% of invasive pneumococcal disease types

Dosage & Administration

• 0.5 mL dose
• 25 micrograms of each of the 23 pneumococcal polysaccharide serotypes
• Administered by intramuscular or subcutaneous injection
• Recommended primary vaccination for adults and children of 2 years of age or older
• Special dosing for patients undergoing elective splenectomy or initiating chemotherapy
• Revaccination guidance for adults and children
• Revaccination interval recommendation
• Revaccination consideration for high-risk groups

Interaction

• Can be administered simultaneously with influenza vaccine
• Requires the use of different needles and injection sites

Contraindications

• Allergic reactions to any vaccine component
• Presence of fever, acute infection, or chronic diseases at the acute stage
• Uncontrolled epilepsy or progressive nervous system diseases

Side Effects

• Common adverse reactions
• Injection-site pain/soreness/tenderness
• Injection-site swelling/induration
• Headache
• Injection-site erythema
• Asthenia and fatigue
• Myalgia

Pregnancy & Lactation

• Use caution during pregnancy
• Unknown excretion in human milk
• Insufficient data from fertility studies

Precautions & Warnings

• Delay in use during febrile illness or active infection
• Avoid intravascular or intradermal injection
• Reduced immune response in immunosuppressed patients
• Possible need for prophylactic antibiotic therapy
• Adequate treatment provisions including epinephrine
• Requirement to continue prophylactic antibiotic therapy against pneumococcal infection

Therapeutic Class

• Vaccines
• Anti-sera
• Immunoglobulin

Storage Conditions

• Refrigerated storage at 2°C to 8°C
• Protection of vials from light

Related Brands